Competition Commission slams company for drug pricing that saw cancer patients go without treatment

  • 📰 TimesLIVE
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 59%

Business News News

'The commission has prioritised this case because the impact of excessive pricing of Trastuzumab falls heavily on women, particularly poor women, who cannot access essential treatment because they cannot afford to pay for it,' competition commissioner ...

At the time the organisation said: “Roche is able to charge such a high price as it holds multiple patents on the drug, which may block cheaper biosimilars from being sold in SA until 2033.”

He said the commission’s investigation found that the excessive pricing conduct took place between January 2011 and November 2020 in the South African private healthcare sector, and in the South African public healthcare sector during the period November 9 to July 2020. Value-based price benchmarks — the commission relied on ratios estimating the additional value and/or the benefit attributable to Trastuzumab against the income per capita — a proxy of the affordability of Trastuzumab.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

I have lost so much through investing cause I was new and didn't meet the right account manager to invest with. I was at the verge of quitting till I was introduced to Mhiz bettyofficial9 and my story Change. it's worth a try I can testify on this platform..

I never thought of meeting a legit bitcoin trader after been scammed many times at my age but the heavens sent williamchurch09 guided me and help me make a living through bitcoin with my coinbase app, I recommend you to meet him now and also be a beneficiary of good work

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 28. in BUSİNESS

Business Business Latest News, Business Business Headlines